FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080996543> ?p ?o ?g. }

• W2080996543 endingPage "93" @default.
• W2080996543 startingPage "85" @default.
• W2080996543 abstract "Transcatheter aortic valve implantation (TAVI) is a new method for the treatment of high-risk patients with aortic valve stenosis. Although a logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) of more than 40% has been considered a contraindication for this new procedure, we routinely perform this procedure in this very high-risk patient group. We analyzed the results of TAVI patients with a EuroSCORE of over 40%.Between April 2008 and January 2012, 514 consecutive patients underwent TAVI. In the study group (group I, EuroSCORE > 40%) of 186 patients the EuroSCORE was 63% ± 16% (range 40 to 98) and the Society of Thoracic Surgeons predicted risk of mortality score was 23% ±14% (range 4 to 90); there were 26 (14%) patients in cardiogenic shock. The mean age was 81 ± 8 (range 36 to 99) years and there were 122 women and 64 men. Group II (the control group, EuroSCORE < 40%) consisted of 328 patients. In this group the EuroSCORE was significantly lower (23% ± 9%, range 2% to 40%). The STS mortality score was 11% ± 8% (1% to 48%). In this group were 196 men and 132 women with a mean age of 78 ± 8 (range 29 to 97) years.Technically, in group I the valve was successfully implanted in 99.5% (185 of 186). In 25 (13%) patients the procedure was performed on the heart-lung machine and in 25 (13%) patients an elective percutaneous coronary intervention was performed in the same session. Postoperative echocardiography showed a low transvalvular gradient (mean 4.5% ± 2.5%, range 2 to 15) and a low rate of paravalvular regurgitation (grade 0 in 97, less than grade I in 49, less than grade II in 38 patients, and grade II in 2 patients). The overall 30-day mortality in patients with EuroSCORE of over 40% (group I), including that in patients in cardiogenic shock, was 6.5%, and in patients with EuroSCORE of over 40% (group I) and without cardiogenic shock it was 5.7%; the 1-year survival was 67% and 71%, respectively, and the 2-year survival was 54% and 56%, respectively.Patients with comorbidities, as mirrored by a EuroSCORE of more than 40% should not be refused for TAVI. On the contrary, this is a supreme indication for the TAVI procedure." @default.
• W2080996543 created "2016-06-24" @default.
• W2080996543 creator A5013926561 @default.
• W2080996543 creator A5017562137 @default.
• W2080996543 creator A5040644396 @default.
• W2080996543 creator A5044946094 @default.
• W2080996543 creator A5055058077 @default.
• W2080996543 creator A5055628594 @default.
• W2080996543 creator A5082842384 @default.
• W2080996543 creator A5088568884 @default.
• W2080996543 creator A5089324914 @default.
• W2080996543 date "2013-01-01" @default.
• W2080996543 modified "2023-10-05" @default.
• W2080996543 title "Transcatheter Aortic Valve Implantation in Very High-Risk Patients With EuroSCORE of More Than 40%" @default.
• W2080996543 cites W135480334 @default.
• W2080996543 cites W1532210414 @default.
• W2080996543 cites W192356090 @default.
• W2080996543 cites W1964917709 @default.
• W2080996543 cites W1975093525 @default.
• W2080996543 cites W1981355443 @default.
• W2080996543 cites W1993784714 @default.
• W2080996543 cites W2002671007 @default.
• W2080996543 cites W2014062021 @default.
• W2080996543 cites W2014547964 @default.
• W2080996543 cites W2014766956 @default.
• W2080996543 cites W2016326104 @default.
• W2080996543 cites W2049281533 @default.
• W2080996543 cites W2073506886 @default.
• W2080996543 cites W2102688307 @default.
• W2080996543 cites W2103277510 @default.
• W2080996543 cites W2108007523 @default.
• W2080996543 cites W2115635386 @default.
• W2080996543 cites W2124719174 @default.
• W2080996543 cites W2149609916 @default.
• W2080996543 cites W2150047811 @default.
• W2080996543 cites W2156202966 @default.
• W2080996543 cites W2157904093 @default.
• W2080996543 cites W2161453256 @default.
• W2080996543 cites W2164084177 @default.
• W2080996543 cites W2890269455 @default.
• W2080996543 cites W4307833091 @default.
• W2080996543 cites W4362062050 @default.
• W2080996543 cites W88822715 @default.
• W2080996543 doi "https://doi.org/10.1016/j.athoracsur.2012.08.055" @default.
• W2080996543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23141527" @default.
• W2080996543 hasPublicationYear "2013" @default.
• W2080996543 type Work @default.
• W2080996543 sameAs 2080996543 @default.
• W2080996543 citedByCount "17" @default.
• W2080996543 countsByYear W20809965432013 @default.
• W2080996543 countsByYear W20809965432014 @default.
• W2080996543 countsByYear W20809965432015 @default.
• W2080996543 countsByYear W20809965432016 @default.
• W2080996543 countsByYear W20809965432017 @default.
• W2080996543 countsByYear W20809965432018 @default.
• W2080996543 countsByYear W20809965432020 @default.
• W2080996543 crossrefType "journal-article" @default.
• W2080996543 hasAuthorship W2080996543A5013926561 @default.
• W2080996543 hasAuthorship W2080996543A5017562137 @default.
• W2080996543 hasAuthorship W2080996543A5040644396 @default.
• W2080996543 hasAuthorship W2080996543A5044946094 @default.
• W2080996543 hasAuthorship W2080996543A5055058077 @default.
• W2080996543 hasAuthorship W2080996543A5055628594 @default.
• W2080996543 hasAuthorship W2080996543A5082842384 @default.
• W2080996543 hasAuthorship W2080996543A5088568884 @default.
• W2080996543 hasAuthorship W2080996543A5089324914 @default.
• W2080996543 hasConcept C126322002 @default.
• W2080996543 hasConcept C141071460 @default.
• W2080996543 hasConcept C142724271 @default.
• W2080996543 hasConcept C164705383 @default.
• W2080996543 hasConcept C204787440 @default.
• W2080996543 hasConcept C2776494729 @default.
• W2080996543 hasConcept C2776570981 @default.
• W2080996543 hasConcept C2776850375 @default.
• W2080996543 hasConcept C2778789114 @default.
• W2080996543 hasConcept C2779040412 @default.
• W2080996543 hasConcept C2780007028 @default.
• W2080996543 hasConcept C2780714102 @default.
• W2080996543 hasConcept C2780813298 @default.
• W2080996543 hasConcept C2781414266 @default.
• W2080996543 hasConcept C500558357 @default.
• W2080996543 hasConcept C71924100 @default.
• W2080996543 hasConceptScore W2080996543C126322002 @default.
• W2080996543 hasConceptScore W2080996543C141071460 @default.
• W2080996543 hasConceptScore W2080996543C142724271 @default.
• W2080996543 hasConceptScore W2080996543C164705383 @default.
• W2080996543 hasConceptScore W2080996543C204787440 @default.
• W2080996543 hasConceptScore W2080996543C2776494729 @default.
• W2080996543 hasConceptScore W2080996543C2776570981 @default.
• W2080996543 hasConceptScore W2080996543C2776850375 @default.
• W2080996543 hasConceptScore W2080996543C2778789114 @default.
• W2080996543 hasConceptScore W2080996543C2779040412 @default.
• W2080996543 hasConceptScore W2080996543C2780007028 @default.
• W2080996543 hasConceptScore W2080996543C2780714102 @default.
• W2080996543 hasConceptScore W2080996543C2780813298 @default.
• W2080996543 hasConceptScore W2080996543C2781414266 @default.
• W2080996543 hasConceptScore W2080996543C500558357 @default.
• W2080996543 hasConceptScore W2080996543C71924100 @default.

• next